Replies to post #8081 on Arch Therapeutics Inc (fka ARTHQ)

[UFO]

Insider trading leaves a HUGE fingerprint. SEC forms have to be filed and they're easy to check. No insider trading happened here.

UFO

[Amatuer17]

FDA probably did not require another trial - if it was the case co had to disclose. (Look at BTCY approval cycle)

I am surprised that co did not disclose when they got questions from FDA for the 1st time and had to respond.

So to me it seems preparation of commercialization of drug - which includes ability to produce adequate quantity of drug with proper GMP - storage - packaging among others

Based on CEB delay - I clearly suspect it is manufacturing issues or GMP certification as the key issue